Respiratory
-
Formulary decision guideStalpex (salmeterol xinafoate/fluticasone propionate)
Information intended for healthcare professionals only. This formulary decision guide was developed from content provided by Glenmark Pharmaceuticals Europe Ltd in a format developed by Guidelines in Practice . View prescribing information here Key points Stalpex is a branded generic inhaled ...
-
Key learning points
Key learning points: uncontrolled and severe asthma
Dr Mark L Levy presents five key learning points to help GPs diagnose and manage patients with difficult-to-treat and severe asthma and identify those who need referral to specialist care
-
Formulary decision guide
Soprobec (beclometasone dipropionate) pMDI
Information intended for healthcare professionals only. This formulary decision guide was developed from content provided by Glenmark Pharmaceuticals Europe Ltd in a format developed by Guidelines in Practice . View prescribing information here Key points Soprobec is a generic CFC-free beclometasone ...
-
On demand webinars
Introduction and implementation of the NICE asthma guidelines
This webinar has been commissioned by Teva UK Limited and organised in partnership with Guidelines in Practice . See bottom of page for full disclaimer. Video: Teva asthma webinar Chapter 1 (4m 4s): Dr Richard Russell—NICE and BTS/SIGN ...
-
Pharmacist focus
Asthma: the role of the practice pharmacist
Garry McDonald describes the key elements of an asthma annual review and explains how practice pharmacists can support asthma management in primary care
-
Formulary decision guide
Symbicort® (budesonide/formoterol) for COPD
Information intended for healthcare professionals only. This formulary decision guide was commissioned by AstraZeneca UK Ltd, who had full editorial control, and was produced in a format developed by Guidelines in Practice . Indications Symbicort pMDI 200 μg/6 μg per actuation, pressurised inhalation suspension, Symbicort ...
-
Implementing guidelines
GOLD 2019 report: a step towards personalised medicine
Professor David Halpin provides an overview of new recommendations in the latest revision to the GOLD COPD strategy
-
Formulary decision guide
Spiriva® Respimat® (tiotropium)
Information intended for healthcare professionals only. This formulary decision guide was developed from content provided by Boehringer Ingelheim Limited in a format developed by Guidelines in Practice . Boehringer Ingelheim Limited reviewed the content for compliance with the ABPI code of practice. View prescribing information here ...
-
Supplement
A comparison of once-daily triple therapy with once-daily dual therapy in the treatment of symptomatic COPD—the IMPACT trial
This supplement has been developed in partnership with GlaxoSmithKline. GlaxoSmithKline suggested the topic, funded production of the supplement, and suggested the author(s); the content has also been checked for factual accuracy to ensure it is fair and balanced, and to ensure its compliance with appropriate regulation. The sponsorship ...
-
News
2019 GOLD COPD strategy published
The Global Initiative for Chronic Obstructive Lung Disease has published the 2019 edition of the Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.
